679405-24-4

Upstream product

• 679405-22-2 6-Chloro-3-[2-(3-chloro-2,6-difluoro-phenyl)-imidazol-1-ylmethyl]-4-methoxy-pyridazine 
• 121359-48-6 2-(tri-n-butylstannyl)thiazole 
• 190011-87-1 1-(3-chloro-2,6-difluoro-phenyl)-carboxaldehyde 
• 83878-89-1 2-diazo-3-oxo-pentanedioic acid dimethyl ester 
• 372118-00-8 4,6-dihydroxy-pyridazine-3-carboxylic acid methyl ester 
• 679405-88-0 2-(3-chloro-2,6-difluoro-phenyl)-imidazole 
• 372118-01-9 4,6-dichloro-pyridazine-3-carboxylic acid methyl ester 
• 679405-85-7 6-chloro-4-methoxypyridazine-3-carboxylic acid methyl ester 
• 679405-87-9 6-chloro-3-chloromethyl-4-methoxypyridazine 
• 679405-86-8 (6-chloro-4-methoxypyridazin-3-yl)methanol 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 

Relevant academic research and scientific papers

Imidazol-1-ylmethyl pyridazine derivatives

The invention provides imidazol-1-ylmethyl pyridazine derivatives of the formula: 1 that bind to GABAA receptors. In the above formula, R1, R2 R3, R4, R5, R6 and Ar are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).